Breaking News Instant updates and real-time market news.

GERN

Geron

$1.34

-0.02 (-1.48%)

, NLNK

NewLink Genetics

$1.60

-0.065 (-3.92%)

18:46
09/30/19
09/30
18:46
09/30/19
18:46

Fly Intel: After Hours Movers

HIGHER: Geron (GERN) up 19.6% after FDA granted imetelstat Fast Track designation in MF treatment...NewLink Genetics (NLNK) up 6.9% after buyig Lumos Pharma. LOWER: AnaptysBio (ANAB) down 17.1% after disclosing Phase 2 data for ANB019... Reed's (REED) down 9.2% after announcing restructuring and naming a new CEO... Five Prime (FPRX) down 1.2% after being downgraded to Neutral at Guggenheim. Movers as of 18:30ET.

GERN

Geron

$1.34

-0.02 (-1.48%)

NLNK

NewLink Genetics

$1.60

-0.065 (-3.92%)

ANAB

AnaptysBio

$34.96

-0.26 (-0.74%)

REED

Reed's

$1.30

(0.00%)

FPRX

Five Prime

$3.87

-0.4 (-9.37%)

  • 01

    Oct

  • 02

    Oct

  • 17

    Oct

  • 21

    Oct

  • 22

    Oct

GERN Geron
$1.34

-0.02 (-1.48%)

04/09/19
04/09/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Outperform from Market Perform at Cowen with analyst Doug Creutz saying he views Disney's "catalyst path for the next year as highly attractive" and believes Thursday's investor day will likely be a "deck-clearing event for sentiment." 2. Comcast (CMCSA) upgraded to Outperform from Neutral at Macquarie with analyst Amy Young saying she remains bullish on pure-play Altice and efforts across Sky, Xfinity, and NBCU. 3. Geron (GERN) upgraded to Buy from Hold at Needham with analyst Chad Messer saying the return of development rights for imetelstat in September by Janssen (JNJ) has created a "buying opportunity." 4. Public Storage (PSA) upgraded to Hold from Underperform at Jefferies with analyst Omotayo Okusanya saying with interest rates set to be lower for longer, equity risk premiums have dropped. 5. PerkinElmer (PKI) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Patrick Donnelly saying the continuation of the company's growth acceleration should exceed "conservative" expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/03/19
HCWC
09/03/19
INITIATION
Target $4
HCWC
Buy
Geron initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino started Geron with a Buy rating and $4 price target. The analyst says he's bullish on the shares based on the return of global rights to imetelstat from Janssen, which he thinks has the potential to result in higher returns, the potential of imetelstat to decrease red blood cell transfusion dependence in patients suffering with low- or intermediate-1 risk myelodysplastic syndromes, and the potential of imetelstat to have a disease-modifying effect in patients suffering with myelofibrosis. Geron's potential for increased returns from full global rights to imetelstat is underappreciated by investors, Bernardino tells investors in a research note.
08/15/19
CANT
08/15/19
INITIATION
Target $4
CANT
Overweight
Geron initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan started Geron with an Overweight rating and $4 price target. Geron's "first-in-class" telomerase inhibitor imetelstat leverages a novel drug target to address myelodysplastic syndrome and myeloproliferative neoplasms, Duncan tells investors in a research note. The analyst views the company's shares as undervalued.
06/28/19
RILY
06/28/19
NO CHANGE
Target $4.5
RILY
Buy
Geron price target raised to $4.50 from $3.25 at B. Riley FBR
B. Riley FBR analyst George Zavoico raised his price target for Geron to $4.50 from $3.25 after the company recently presented new results from its two trials of imetelstat in two different blood cancers. The results provide "strong evidence" of safety and efficacy that is "markedly superior" to current standard of care, Zavoico tells investors in a research note. He keeps a Buy rating on Geron.
NLNK NewLink Genetics
$1.60

-0.065 (-3.92%)

01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Underperform
NewLink Genetics downgraded to Underperform from Neutral at BofA/Merrill
01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Underperform
NewLink Genetics downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded NewLink Genetics to Underperform from Neutral and lowered its price target to $1 from $5. Analyst Ying Huang said he lacks conviction for indoximod after epacadostat efficacy in Phase 3 study was underwhelming.
ANAB AnaptysBio
$34.96

-0.26 (-0.74%)

06/21/19
JEFF
06/21/19
NO CHANGE
JEFF
Buy
Jefferies reiterates Buy on AnaptysBio, says Regeneron data 'best case'
Jefferies analyst Biren Amin says that while the selloff this morning in AnaptysBio (ANAB) shares suggests that its etokimab has lower odds after Regeneron's (REGN) REGN3500 data, the data from Regeneron are actually a "best case scenario." The combo of REGN3500 and Dupixent did not offer any additional benefit, says the analyst, who viewed that arm as the greatest long-term risk to etokimab. Also, not all antibodies are built the same, Amin tells investors in a research note titled "Don't Throw The Baby Out With Bathwater; A Lesson To Be Learned From AMG-317." He notes that AMG-317 failed in asthma, and targets IL-4, and yet Dupixent has seen success. The analyst reiterates a Buy rating on AnaptysBio and awaits the company's data in the second half of the year. The stock in early trading is down 15%, or $9.82, to $57.20.
06/21/19
06/21/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Carnival (CCL) downgraded to Equal Weight from Overweight at Barclays with analyst Felicia Hendrix saying the company's challenges in Europe, which could continue into next year, make it difficult to justify the sane Overweight rating that is on peers Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH). 2. Caterpillar (CAT) downgraded to Underweight from Neutral at Atlantic Equities. 3. Grainger (GWW) downgraded to Underweight from Neutral at Atlantic Equities. 4. AnaptysBio (ANAB) downgraded to Neutral from Outperform at Credit Suisse and to Hold from Buy at Stifel. 5. Sealed Air (SEE) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos citing the company's announcement that its board terminated William Stiehl as Chief Financial Officer for cause relating to the process by which the company selected its independent audit firm. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/24/19
RHCO
06/24/19
NO CHANGE
RHCO
AnaptysBio price target lowered to $93 from $125 at SunTrust, maintain Buy
SunTrust analyst Joon Lee maintained a Buy rating on Anaptys Bio but lowered his price target to $93 from $125 after a competitor drug with the same target as etokimab failing to meaningfully differentiate from dupilumab. However, the analyst still views etokimab as a viable drug in markets large enough to sustain multiple drugs.
08/20/19
CANT
08/20/19
NO CHANGE
Target $140
CANT
Overweight
Cantor says AnaptysBio CFO resignation likely has no read to ongoing studies
After speaking to AnaptysBio management, Cantor Fitzgerald analyst Eliana Merle said she thinks the resignation of CFO Dominic Piscitelli likely has no read-through to the company's ongoing clinical studies, which all remain blinded. While "optically this timing might not be ideal," management reiterated that all clinical timelines remain on track and her sense is that Piscitelli was approached with a compelling opportunity, the analyst tells investors. Merle keeps an Overweight rating on AnaptysBio shares with a $140 price target.
REED Reed's
$1.30

(0.00%)

05/10/19
RFLF
05/10/19
INITIATION
Target $5
RFLF
Buy
Reed's initiated with a Buy at RF Lafferty
RF Lafferty analyst Roger Duan started Reed's with a Buy rating and $5 price target, citing the company's accelerating growth under new management, its leading position in craft beverages and its launch of several new products, including some with CBD.
05/10/19
05/10/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wayfair (W) initiated with a Sell at Berenberg. 2. United Technologies (UTX) initiated with a Neutral at Seaport Global. 3. Alcon (ALC) initiated with an Outperform at Baird. 4. Pinterest (PINS) initiated with a Buy at Nomura Instinet and a Hold at Argus. 5. Reed's (REED) initiated with a Buy at RF Lafferty. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/26/19
LSCM
04/26/19
INITIATION
Target $6
LSCM
Buy
Reed's initiated with a Buy at Lake Street
Lake Street analyst Chris Krueger started Reed's with a Buy rating and $6 price target. The analyst believes the company is well positioned to take advantage of the "healthy consumer trend with its unique, handcrafted beverage products." Reed's will return to growth mode in 2019, with increasing margins, Krueger tells investors in a research note. He believes the company can grow sales annually at 20% for the next several years and could eventually become a takeout candidate for a larger beverage company. The stock should move higher as Reed's is awarded a growth multiple and revenues accelerate, contends Krueger.
04/26/19
04/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Vail Resorts (MTN) initiated with a Buy at SunTrust. 2. Tocagen (TOCA) initiated with an Overweight at Cantor Fitzgerald. 3. Dow Inc. (DOW) initiated with a Hold at Argus. 4. Gilead (GILD) initiated with an Outperform at Bernstein. 5. Reed's (REED) initiated with a Buy at Lake Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
FPRX Five Prime
$3.87

-0.4 (-9.37%)

06/03/19
06/03/19
DOWNGRADE
Target $10

Market Perform
Five Prime downgraded to Market Perform following ASCO data at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough downgraded Five Prime Therapeutics to Market Perform from Outperform following review of data at ASCO for B7:H4 antibody FPA-150 in B7:H4+ patients with solid tumors including ovarian cancer. The analyst says overall response rate of 1/18 in B7:H4+ tumors was "underwhelming," with lack of clarity on dose response. Birchenough also lowered his price target on the shares to $10 from $35.
06/03/19
WELS
06/03/19
DOWNGRADE
Target $10
WELS
Market Perform
Five Prime downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo Securities analyst Jim Birchenough downgraded Five Prime Therapeutics to Market Perform from Outperform and lowered his price target for the shares to $10 from $35.
05/28/19
ROTH
05/28/19
INITIATION
Target $10
ROTH
Neutral
Five Prime initiated with a Neutral at Roth Capital
Roth Capital analyst Tony Butler initiated Five Prime with a Neutral rating and a price target of $10. The analyst is positive on the company's "robust protein therapeutics platform" with additional upside potentially coming from its expected clinical updates from two early stage programs, also noting that the recent profitability efforts could also make it an "appealing M&A target". Butler warns however that "significant overhang" exists over Five Prime's lead Bemarituzumab program.
09/30/19
GUGG
09/30/19
DOWNGRADE
GUGG
Neutral
Five Prime downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Michael Schmidt downgraded Five Prime Therapeutics to Neutral from Buy.

TODAY'S FREE FLY STORIES

03:20
11/15/19
11/15
03:20
11/15/19
03:20
General news
FX Update: The dollar and yen have traded softer »

FX Update: The dollar and…

01:45
11/15/19
11/15
01:45
11/15/19
01:45
General news
Asian Market Update: »

Asian Market Update:…

PAYS

Paysign

$11.27

-0.56 (-4.73%)

20:32
11/14/19
11/14
20:32
11/14/19
20:32
Initiation
Paysign initiated at DA Davidson »

Paysign initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 25

    Nov

  • 26

    Nov

LPTX

Leap Therapeutics

$0.57

-0.5922 (-50.83%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Downgrade
Leap Therapeutics rating change at Raymond James »

Leap Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$100.07

0.38 (0.38%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Upgrade
Fortinet rating change at Credit Suisse »

Fortinet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 18

    Nov

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

JD

JD.com

$33.57

0.21 (0.63%)

, WVE

Wave Life Sciences

$27.90

-0.07 (-0.25%)

20:25
11/14/19
11/14
20:25
11/14/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JD

JD.com

$33.57

0.21 (0.63%)

WVE

Wave Life Sciences

$27.90

-0.07 (-0.25%)

RYTM

Rhythm Pharmaceuticals

$21.52

0.38 (1.80%)

JCP

J.C. Penney

$1.10

0.01 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 09

    Dec

SBS

Sabesp

$12.21

-0.02 (-0.16%)

20:22
11/14/19
11/14
20:22
11/14/19
20:22
Earnings
Sabesp reports Q3 adjusted EBITDA up 109.8% at BRL3.01B »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

LINX

Linx S.A.

$7.11

-0.8 (-10.11%)

19:16
11/14/19
11/14
19:16
11/14/19
19:16
Recommendations
Linx S.A. analyst commentary at Jefferies »

Linx S.A. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CNP

CenterPoint Energy

$26.68

-1.42 (-5.05%)

19:12
11/14/19
11/14
19:12
11/14/19
19:12
Downgrade
CenterPoint Energy rating change at Credit Suisse »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$309.54

0.46 (0.15%)

19:09
11/14/19
11/14
19:09
11/14/19
19:09
Periodicals
Kudlow says U.S. near trade agreement with China, Reuters says »

White House economic…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$309.54

0.46 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$75.55

-0.54 (-0.71%)

18:41
11/14/19
11/14
18:41
11/14/19
18:41
Hot Stocks
BioMarin CEO: Our products have a very long life cycle »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

OXY

Occidental Petroleum

$37.76

-0.36 (-0.94%)

18:38
11/14/19
11/14
18:38
11/14/19
18:38
Periodicals
Judge rejects Icahn's suit seeking Occidental acquisition records, Reuters says »

A Delaware court judge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

, DGII

Digi International

$15.10

0.33 (2.23%)

18:35
11/14/19
11/14
18:35
11/14/19
18:35
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

FTCH

Farfetch

$7.49

-0.54 (-6.72%)

DGII

Digi International

$15.10

0.33 (2.23%)

AMAT

Applied Materials

$56.89

-0.24 (-0.42%)

KLIC

Kulicke & Soffa

$25.18

-0.22 (-0.87%)

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

WPM

Wheaton Precious Metals

$26.47

-0.12 (-0.45%)

RDNT

RadNet

$15.92

0.09 (0.57%)

RH

RH

$175.19

1.98 (1.14%)

ACB

Aurora Cannabis

$3.29

-0.25 (-7.06%)

OSMT

Osmotica Pharmaceuticals

$4.00

-0.03 (-0.74%)

GLOB

Globant

$108.99

3.975 (3.79%)

DLB

Dolby

$65.56

-0.14 (-0.21%)

NVDA

Nvidia

$209.88

1.33 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

  • 20

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 06

    Jan

VIA

Viacom

$25.31

0.175 (0.70%)

, VIAB

Viacom

$22.48

0.44 (2.00%)

18:24
11/14/19
11/14
18:24
11/14/19
18:24
Hot Stocks
Viacom CEO: The road ahead for the company is very exciting »

In an interview on…

VIA

Viacom

$25.31

0.175 (0.70%)

VIAB

Viacom

$22.48

0.44 (2.00%)

CBS

CBS

$37.62

0.78 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 09

    Dec

NVDA

Nvidia

$209.88

1.33 (0.64%)

18:22
11/14/19
11/14
18:22
11/14/19
18:22
Hot Stocks
Breaking Hot Stocks news story on Nvidia »

Nvidia CFO says continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

NVDA

Nvidia

$209.88

1.33 (0.64%)

18:04
11/14/19
11/14
18:04
11/14/19
18:04
Hot Stocks
Nvidia CEO says Q4 will be much stronger driven by AI and inference »

Says computational…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

BABA

Alibaba

$182.69

0.21 (0.12%)

17:50
11/14/19
11/14
17:50
11/14/19
17:50
Syndicate
Alibaba launches Hong Kong IPO »

Alibaba Group Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Conference/Events
William Blair SaaS analyst to hold a luncheon meeting »

SaaS Analyst Pfau holds a…

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Earnings
Helmerich & Payne sees FY20 CapEx approximately $275M-$300M »

57-62% expected for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

PPG

PPG

$129.82

-0.5 (-0.38%)

, PG

Procter & Gamble

$120.49

-0.15 (-0.12%)

17:49
11/14/19
11/14
17:49
11/14/19
17:49
Hot Stocks
Trian Fund exits PPG, cuts Wendy's in Q3 »

Nelson Peltz' Trian…

PPG

PPG

$129.82

-0.5 (-0.38%)

PG

Procter & Gamble

$120.49

-0.15 (-0.12%)

MDLZ

Mondelez

$52.90

0.2 (0.38%)

LM

Legg Mason

$38.60

-0.22 (-0.57%)

GE

General Electric

$11.30

-0.01 (-0.09%)

WEN

Wendy's

$20.90

-0.01 (-0.05%)

BK

BNY Mellon

$48.42

0.07 (0.14%)

SYY

Sysco

$81.51

0.27 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 02

    Dec

  • 11

    Dec

  • 16

    Jan

  • 29

    Jan

HP

Helmerich & Payne

$39.30

0.04 (0.10%)

17:48
11/14/19
11/14
17:48
11/14/19
17:48
Earnings
Helmerich & Payne reports Q4 cont ops EPS 38c, consensus 23c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

17:47
11/14/19
11/14
17:47
11/14/19
17:47
Conference/Events
DA Davidson software analysts to hold a dinner meeting »

Analysts host a Security…

MDCO

The Medicines Co.

$50.89

-1.905 (-3.61%)

17:46
11/14/19
11/14
17:46
11/14/19
17:46
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

NVDA

Nvidia

$209.88

1.33 (0.64%)

17:44
11/14/19
11/14
17:44
11/14/19
17:44
Hot Stocks
Nvidia CFO says Q3 decline in automotive revenue driven by one-time item »

Says AI cockbit business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 06

    Jan

CPE

Callon Petroleum

$4.20

-0.265 (-5.94%)

, PSDO

Presidio

$16.56

-0.02 (-0.12%)

17:44
11/14/19
11/14
17:44
11/14/19
17:44
Hot Stocks
Paulson adds Callon Petroleum, lowers stake in Lyft in Q3 »

John Paulson's…

CPE

Callon Petroleum

$4.20

-0.265 (-5.94%)

PSDO

Presidio

$16.56

-0.02 (-0.12%)

OSG

Overseas Shipholding

$1.84

0.045 (2.51%)

STC

Stewart

$43.10

0.11 (0.26%)

AGN

Allergan

$182.47

0.91 (0.50%)

HZNP

Horizon Pharma

$29.82

-0.48 (-1.58%)

ONCE

Spark Therapeutics

$110.78

-0.65 (-0.58%)

MYL

Mylan

$17.26

-0.01 (-0.06%)

S

Sprint

$5.86

-0.21 (-3.46%)

LYFT

Lyft

$41.90

-1.39 (-3.21%)

TMUS

T-Mobile

$76.87

-1.15 (-1.47%)

PCG

PG&E

$6.70

-0.19 (-2.76%)

WCG

WellCare

$301.86

-2.56 (-0.84%)

TSU

Tim Participacoes

$15.53

0.44 (2.92%)

GLD

SPDR Gold Shares

$138.57

0.59 (0.43%)

BHC

Bausch Health

$27.77

0.38 (1.39%)

CELG

Celgene

$110.03

-0.42 (-0.38%)

DISCK

Discovery Inc.

$28.04

0.12 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 07

    Jan

  • 25

    Mar

  • 04

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.